PTC Therapeutics (FRA:BH3) Short Percentage of Float

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PTC Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, PTC Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Short Percentage of Float falls into.

PTC Therapeutics (FRA:BH3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

PTCT:USA BH3:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics (FRA:BH3) Headlines

No Headlines